Why a written follow-up plan matters for targeted therapy
Targeted cancer treatment acts on particular molecular features of a tumour, and biomarker findings can help clinicians assess potential treatment options. That makes follow-up different from a simple appointment reminder. The plan needs to connect the specific drug, the biomarker context that supported it, and the monitoring that the treating team considers necessary.
Without a written plan, follow-up can fragment. One clinic holds the imaging, another holds the pathology, and the patient carries verbal instructions that no one can verify. A written plan gives every clinician the same starting point and shows you what still needs confirmation.
This article answers one question: how should reviews, records, contacts and responsibility be documented in writing for targeted cancer therapy in China? It does not confirm that any particular drug is available, that you are suitable for treatment, or that travel is appropriate. Those are decisions for the treating hospital and licensed clinicians.
A written plan is not a substitute for clinical judgement, and it is not a contract. It is a shared reference that you, your family and your clinicians can check when memory or distance creates doubt. The value comes from specificity: a named drug, a named review, a named contact, a named person responsible for each step.
The sections below work through the four things the plan should record, then explain how to request one and what to do when an answer is still missing. Each section ends with a concrete action you can take, rather than a general reminder to stay organised.
What the written plan should record about reviews and monitoring
A useful follow-up plan names the reviews that are planned and explains what each one is for. It should distinguish routine monitoring from reviews triggered by a specific concern, such as a new symptom or a change in test results. The plan should also state what the treating team will do with the results and who will contact you.
Ask the centre to write down the sequence in plain language: which review comes first, what information it depends on, and what happens if a result needs discussion. If the timing depends on how you respond to treatment, the plan should say so rather than give a fixed date that may not hold.
The plan should also record the boundaries. If a review cannot be completed remotely, or if certain assessments require you to be physically present, that should be written down. This is not a reason to delay necessary local care. If you develop urgent or worsening symptoms, seek local assessment first.
For the drug itself, the written plan should identify the specific medicine by its generic name and record the biomarker context that supported its use. It should not assume that every biomarker finding leads to an available treatment. The treating clinician decides whether a biomarker is actionable in your case.
Contacts: who to reach, how, and about what
A written plan should name the contact point for clinical questions and the contact point for administrative questions. These may be different people. The plan should say how each can be reached and what kind of question belongs with each.
Ask the centre to record the expected response route. If you send a question by email, who reads it? If you need a reply before a certain review, how far in advance should you ask? The plan should not promise a response time that the centre cannot keep, but it should explain how the process works.
For anything urgent, the plan should say what to do locally rather than waiting for an overseas reply. A written plan is not an emergency service. If your symptoms worsen, contact local emergency or urgent care.
If a family member or caregiver will act on your behalf, the plan should record who that person is and what they are authorised to discuss. Consent and privacy rules belong to the treating hospital, so ask how that is handled.
Responsibility: who owns each step
A frequent gap in follow-up is not missing information but unclear responsibility. The written plan should state, for each step, whether the treating centre, your home clinician, or you are responsible for making it happen.
For example, if a scan is due, the plan should say who orders it, where it can be done, and who reviews the result. If a prescription needs renewal, the plan should say which clinician can renew it and under what conditions. If a review depends on a report from another hospital, the plan should say who requests that report.
Ask the treating team to write down what they will do and what they expect you to do. This is not a contract, but it gives both sides a shared reference. If something changes, the plan can be updated in writing.
Where responsibility sits with a clinician in your home country, the plan should say so. The receiving clinician makes their own judgement about your care. A written plan supports that judgement by giving them clear information; it does not replace it.
Preparing your request and the next step
Before you ask for a written follow-up plan, gather the basics: the specific drug name, the biomarker results that supported it, your current treatment summary, and the contact details of the clinicians involved. A short, clear request is easier to answer than a long one.
Ask the centre to confirm whether it can assess your case for ongoing targeted therapy and how monitoring would continue. If the answer depends on records you do not yet have, ask which document is needed and who should provide it. Do not assume that a review confirms access to a particular medicine or that treatment can continue in a specific setting.
If you are considering care in China, an initial enquiry is free and does not require buying a proxy consultation. You can start with a brief summary of your diagnosis, the drug and biomarker context, and your main question. The team can then explain what information is missing and what the relevant next step is.
For general information on how targeted therapy is planned and reviewed, see the related page on targeted cancer therapy. Use it alongside the written plan from your treating centre, not as a substitute for it.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.